Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
VBI Vaccines, Inc. - Ordinary Shares
(NQ:
VBIV
)
0.0653
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about VBI Vaccines, Inc. - Ordinary Shares
< Previous
1
2
3
4
Next >
VBI Vaccines Provides an Update on its Restructuring Proceedings
August 02, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
July 30, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Results of Annual General Meeting
June 25, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
May 29, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
May 22, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Reports First Quarter 2024 Financial Results
May 15, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Reports Full Year 2023 Financial Results
April 16, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 11, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 09, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
April 03, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
April 02, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
February 14, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
November 20, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Reports Third Quarter 2023 Financial Results
November 14, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
October 26, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
September 27, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
September 07, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
September 06, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Reports Second Quarter 2023 Financial Results
August 14, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares
July 24, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults
July 19, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering
July 06, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants
July 05, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties
July 05, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Results of Annual General Meeting
June 23, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults
June 15, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Poster Presentation at EASL 2023
June 07, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Reports First Quarter 2023 Financial Results
May 15, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Appoints Vaughn Himes to Board of Directors
April 25, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split
April 04, 2023
From
VBI Vaccines Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
